Diagnostic Potential of Plasma Carboxymethyllysine and Carboxyethyllysine in Multiple Sclerosis

Overview

Journal J Neuroinflammation

Publisher Biomed Central

Date 2010 Nov 2

PMID 21034482

Citations 18

Authors

Zohara Sternberg

Cassandra Hennies

Daniel Sternberg

Ping Wang

Peter Kinkel

David Hojnacki

Bianca Weinstock-Guttmann

Frederick Munschauer

Affiliations

Soon will be listed here.

Abstract

Background: This study compared the level of advanced glycation end products (AGEs), N-(Carboxymethyl)lysine (CML) and N-(Carboxyethyl)lysine (CEL), in patients with multiple sclerosis (MS) and healthy controls (HCs), correlating these markers with clinical indicators of MS disease severity.

Methods: CML and CEL plasma levels were analyzed in 99 MS patients and 43 HCs by tandem mass spectrometry (LC/MS/MS). Patients were stratified based on drug modifying therapies (DMTs) including interferon beta, glatiramer acetate and natalizumab.

Results: The level of plasma CEL, but not CML, was significantly higher in DMT-naïve MS patients when compared to HCs (P < 0.001). Among MS patients, 91% had higher than mean plasma CEL observed in HCs. DMTs reduced CML and CEL plasma levels by approximately 13% and 40% respectively. CML and CEL plasma levels correlated with the rate of MS clinical relapse.

Conclusion: Our results suggest that AGEs in general and CEL in particular could be useful biomarkers in MS clinical practice. Longitudinal studies are warranted to determine any causal relationship between changes in plasma level of AGEs and MS disease pathology. These studies will pave the way for use of AGE inhibitors and AGE-breaking agents as new therapeutic modalities in MS.

Citing Articles

Dietary galactose exacerbates autoimmune neuroinflammation advanced glycation end product-mediated neurodegeneration.

Haase S, Kuhbandner K, Muhleck F, Gisevius B, Freudenstein D, Hirschberg S Front Immunol. 2024; 15:1367819.

PMID: 39185426 PMC: 11341352. DOI: 10.3389/fimmu.2024.1367819.

Carboxymethyllysine and carboxyethyllysine in multiple sclerosis patients.

Damasiewicz-Bodzek A, Labuz-Roszak B, Kumaszka B, Tyrpien-Golder K Arch Med Sci. 2024; 20(3):736-742.

PMID: 39050184 PMC: 11264072. DOI: 10.5114/aoms.2020.95654.

Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease.

Lai S, Lopez Gonzalez E, Zoukari T, Ki P, Shuck S Chem Res Toxicol. 2022; 35(10):1720-1746.

PMID: 36197742 PMC: 9580021. DOI: 10.1021/acs.chemrestox.2c00160.

KF140 Reduces Dietary Absorption of N - (Carboxymethyl)lysine in Rats and Humans β-Galactosidase Activity.

Park H, Lee H, Lee S, Oh M, Ha S, Do E Front Nutr. 2022; 9:916262.

PMID: 35811971 PMC: 9263842. DOI: 10.3389/fnut.2022.916262.

AGE/Non-AGE Glycation: An Important Event in Rheumatoid Arthritis Pathophysiology.

Monu , Agnihotri P, Biswas S Inflammation. 2021; 45(2):477-496.

PMID: 34787800 DOI: 10.1007/s10753-021-01589-7.

References

Teerlink T, Barto R, Ten Brink H, Schalkwijk C . Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem. 2004; 50(7):1222-8. DOI: 10.1373/clinchem.2004.031286. View

Shen J, Wu Y, Xu J, Zhang J, Sinclair S, Yanoff M . ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci. 2009; 51(1):35-46. DOI: 10.1167/iovs.09-3544. View

Chappey O, Dosquet C, Wautier M, Wautier J . Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest. 1997; 27(2):97-108. DOI: 10.1046/j.1365-2362.1997.710624.x. View

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore G, Tortorella C . Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci. 2009; 286(1-2):109-13. DOI: 10.1016/j.jns.2009.06.036. View

Wolinsky J, Shochat T, Weiss S, Ladkani D . Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J Neurol Sci. 2009; 286(1-2):92-8. DOI: 10.1016/j.jns.2009.04.019. View

Kikuchi S, Shinpo K, Ogata A, Tsuji S, Takeuchi M, Makita Z . Detection of N epsilon-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002; 3(2):63-8. DOI: 10.1080/146608202760196020. View

Qin J, Goswami R, Dawson S, Dawson G . Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J Neurosci Res. 2008; 86(11):2414-22. PMC: 2671024. DOI: 10.1002/jnr.21692. View

Qin J, Goswami R, Balabanov R, Dawson G . Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res. 2007; 85(5):977-84. DOI: 10.1002/jnr.21206. View

Januszewski A, Alderson N, Metz T, Thorpe S, Baynes J . Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans. 2003; 31(Pt 6):1413-6. DOI: 10.1042/bst0311413. View

10.

Calkin A, Giunti S, Sheehy K, Chew C, Boolell V, Rajaram Y . The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia. 2008; 51(9):1731-40. DOI: 10.1007/s00125-008-1060-6. View

11.

Vasan S, Foiles P, Founds H . Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003; 419(1):89-96. DOI: 10.1016/j.abb.2003.08.016. View

12.

Yamagishi S, Matsui T, Nakamura K . Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker. Med Hypotheses. 2006; 68(5):1096-8. DOI: 10.1016/j.mehy.2006.07.059. View

13.

Ahmed M, Brinkmann Frye E, Degenhardt T, Thorpe S, Baynes J . N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J. 1997; 324 ( Pt 2):565-70. PMC: 1218467. DOI: 10.1042/bj3240565. View

14.

Di Loreto S, Caracciolo V, Colafarina S, Sebastiani P, Gasbarri A, Amicarelli F . Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. Brain Res. 2004; 1006(2):157-67. DOI: 10.1016/j.brainres.2004.01.066. View

15.

Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M . Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res. 2005; 1(1):39-46. DOI: 10.2174/1567205043480582. View

16.

Miranda H, Outeiro T . The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol. 2010; 221(1):13-25. DOI: 10.1002/path.2682. View

17.

Peppa M, Vlassara H . Advanced glycation end products and diabetic complications: a general overview. Hormones (Athens). 2006; 4(1):28-37. DOI: 10.14310/horm.2002.11140. View

18.

Sternberg Z, Ostrow P, Vaughan M, Chichelli T, Munschauer F . AGE-RAGE in multiple sclerosis brain. Immunol Invest. 2010; 40(2):197-205. DOI: 10.3109/08820139.2010.532267. View

19.

Gonsette R . Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci. 2008; 274(1-2):48-53. DOI: 10.1016/j.jns.2008.06.029. View

20.

Rysava R, Kalousova M, Zima T, Dostal C, Merta M, Tesar V . Does renal function influence plasma levels of advanced glycation and oxidation protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis?. Kidney Blood Press Res. 2006; 30(1):1-7. DOI: 10.1159/000098140. View